Jennison Associates
PCVX icon

Jennison Associates’s Vaxcyte PCVX Stock Holding History

Jennison Associates’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.7M Sell
476,216
-1,221,795
-72% -$66.4M 0.02% 301
2026
Q1 		$98.7M Buy
1,698,011
+1,020,458
+151% +$55.4M 0.07% 138
2025
Q4 		$31.3M Sell
677,553
-493,346
-42% -$22.1M 0.02% 273
2025
Q3 		$42.2M Sell
1,170,899
-228,400
-16% -$7.57M 0.02% 245
2025
Q2 		$45.5M Buy
1,399,299
+273,579
+24% +$8.97M 0.03% 233
2025
Q1 		$42.5M Sell
1,125,720
-120,831
-10% -$9.66M 0.03% 234
2024
Q4 		$102M Buy
1,246,551
+9,121
+0.7% +$906K 0.06% 141
2024
Q3 		$141M Sell
1,237,430
-145,701
-11% -$13.1M 0.09% 95
2024
Q2 		$104M Buy
1,383,131
+126,248
+10% +$8.59M 0.07% 120
2024
Q1 		$85.9M Sell
1,256,883
-219,271
-15% -$15.2M 0.06% 136
2023
Q4 		$92.7M Sell
1,476,154
-278,537
-16% -$14.5M 0.07% 122
2023
Q3 		$89.5M Buy
1,754,691
+300,189
+21% +$14.8M 0.08% 118
2023
Q2 		$72.6M Buy
1,454,502
+24,463
+2% +$1.16M 0.06% 144
2023
Q1 		$53.6M Buy
1,430,039
+8,032
+0.6% +$341K 0.05% 175
2022
Q4 		$68.2M Buy
+1,422,007
New +$55.8M 0.07% 151

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Jennison Associates's PCVX Position: Q2 2026 in Review

Jennison Associates reduced its Vaxcyte (PCVX) stake by 72% in Q2 2026, selling an estimated $66.4M and leaving 476,216 shares worth $27.7M. The position accounts for 0.02% of the portfolio, ranked #301.

Jennison Associates first reported a position in PCVX in Q4 2022 and has held it in 15 quarters since. The position peaked at $141M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Jennison Associates held 476,216 shares of Vaxcyte worth $27.7M as of Q2 2026.
  • Jennison Associates sold 1,221,795 Vaxcyte shares in Q2 2026, an estimated $66.4M.
  • Vaxcyte made up 0.02% of Jennison Associates's portfolio in Q2 2026, its #301 holding.
  • Jennison Associates first reported a position in Vaxcyte in Q4 2022 and has held it in 15 quarters since.
  • Jennison Associates's Vaxcyte position peaked at $141M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.